An analysis of configurations of relationship quality dimensions to explain sources of behavioral outcomes in globalized manufacturing

Purpose This paper aims to explore the role of configurations of relationship quality dimensions for explaining sources of behavioral outcomes in the globalized manufacturing industry. Design/methodology/approach A joint analysis of behavioral and objective performance data from globalized manufacturing links perceptual customer metrics that relate to dimensions of relationship quality (i.e. attitudinal loyalty, perceived customer orientation, customers’ perceived innovativeness of the supplier and perceived customer influence on supplier innovation) with behavioral outcomes (i.e. share of wallet (SOW) and customer account profitability). Using data from a global business-to-business (B2B) customer survey together with archival performance data from a multinational mechanical engineering firm, a fuzzy set qualitative comparative analysis (fsQCA) is performed.Peer reviewe

Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination

SARS-CoV-2 variants of concern (VOCs) can trigger severe endemic waves and vaccine breakthrough infections (VBI). We analyzed the cellular and humoral immune response in 8 patients infected with the alpha variant, resulting in moderate to fatal COVID-19 disease manifestation, after double mRNA-based anti-SARS-CoV-2 vaccination. In contrast to the uninfected vaccinated control cohort, the diseased individuals had no detectable high-avidity spike (S)-reactive CD4+ and CD8+ T cells against the alpha variant and wild type (WT) at disease onset, whereas a robust CD4+ T-cell response against the N- and M-proteins was generated. Furthermore, a delayed alpha S-reactive high-avidity CD4+ T-cell response was mounted during disease progression. Compared to the vaccinated control donors, these patients also had lower neutralizing antibody titers against the alpha variant at disease onset. The delayed development of alpha S-specific cellular and humoral immunity upon VBI indicates reduced immunogenicity against the S-protein of the alpha VOC, while there was a higher and earlier N- and M-reactive T-cell response. Our findings do not undermine the current vaccination strategies but underline a potential need for the inclusion of VBI patients in alternative vaccination strategies and additional antigenic targets in next-generation SARS-CoV-2 vaccines

CALLISTO: towards reusability of a rocket stage: current status

JAXA, CNES and DLR have decided to cooperate to develop and fly a scaled reusable VTVL rocket stage called CALLISTO (Cooperative Action Leading to Launcher Innovation in Stage Toss - back Operations). This vehicle is paving the way for future reusable launch vehicles in Europe and in Japan. During phase B important progress in term of methods and operation philosophy specific to RLV have been made. Amongst other progresses, that will ease the development of future operational VTVL, in the domain of aerodynamic modelling, GNC landing leg deployment but also flight domain definitions are presented. These are concrete results which can at least partly be useful for other RLV projects

Proceedings of the 4th bwHPC Symposium

The bwHPC Symposium 2017 took place on October 4th, 2017, Alte Aula, Tübingen. It focused on the presentation of scientific computing projects as well as on the progress and the success stories of the bwHPC realization concept. The event offered a unique opportunity to engage in an active dialogue between scientific users, operators of bwHPC sites, and the bwHPC support team

Systemic therapy of Cushing’s syndrome

Cushing’s disease (CD) in a stricter sense derives from pathologic adrenocorticotropic hormone (ACTH) secretion usually triggered by micro- or macroadenoma of the pituitary gland. It is, thus, a form of secondary hypercortisolism. In contrast, Cushing’s syndrome (CS) describes the complexity of clinical consequences triggered by excessive cortisol blood levels over extended periods of time irrespective of their origin. CS is a rare disease according to the European orphan regulation affecting not more than 5/10,000 persons in Europe. CD most commonly affects adults aged 20–50 years with a marked female preponderance (1:5 ratio of male vs. female). Patient presentation and clinical symptoms substantially vary depending on duration and plasma levels of cortisol. In 80% of cases CS is ACTH-dependent and in 20% of cases it is ACTH-independent, respectively. Endogenous CS usually is a result of a pituitary tumor. Clinical manifestation of CS, apart from corticotropin-releasing hormone (CRH-), ACTH-, and cortisol-producing (malign and benign) tumors may also be by exogenous glucocorticoid intake. Diagnosis of hypercortisolism (irrespective of its origin) comprises the following: Complete blood count including serum electrolytes, blood sugar etc., urinary free cortisol (UFC) from 24 h-urine sampling and circadian profile of plasma cortisol, plasma ACTH, dehydroepiandrosterone, testosterone itself, and urine steroid profile, Low-Dose-Dexamethasone-Test, High-Dose-Dexamethasone-Test, after endocrine diagnostic tests: magnetic resonance imaging (MRI), ultra-sound, computer tomography (CT) and other localization diagnostics. First-line therapy is trans-sphenoidal surgery (TSS) of the pituitary adenoma (in case of ACTH-producing tumors). In patients not amenable for surgery radiotherapy remains an option. Pharmacological therapy applies when these two options are not amenable or refused. In cases when pharmacological therapy becomes necessary, Pasireotide should be used in first-line in CD. CS patients are at an overall 4-fold higher mortality rate than age- and gender-matched subjects in the general population. The following article describes the most prominent substances used for clinical management of CS and gives a systematic overview of safety profiles, pharmacokinetic (PK)-parameters, and regulatory framework

Towards a Reusable First Stage Demonstrator: CALLISTO - Technical Progresses & Challenges

In order to investigate the capabilities of a reusable launch system, JAXA, CNES and DLR have jointly initiated the project CALLISTO ("Cooperative Action Leading to Launcher Innovation for Stage Toss-back Operations"). The goal of this cooperation is to launch, recover and reuse a first stage demonstrator to increase the maturity of technologies necessary for future operational reusable launch vehicles (RLV) and to build up know-how on such vehicles under operational and developmental aspects. As the project has now turned into the detailed design phase, significant technical progresses have been made in definition, analysis and testing of systems and subsystems. The CALLISTO vehicle itself constitutes a subscale vertical take-off vertical landing (VTVL) stage with an overall length of 13.5 m and a take-off mass of less than 4 tons, which is propelled by a throttleable LOX/LH2 engine. It is capable to perform up to 10 consecutive flights during the planned flight campaign in French Guiana. Globally, the development effort on this system is equally shared between the three project partners. This paper presents the recent achievements in development of the key technologies for the reusable launch vehicle. While the design of critical subsystems has reached PDR level, detailed analyses and first breadboard tests have been performed successfully. These results are presented and discussed within the perimeter of the CALLISTO development roadmap. Possible technical challenges are indicated and their resolution methods are examined. Finally, the upcoming development steps are described which are foreseen to move forward to the qualification and maiden flight campaign

Do customer perceptions of innovation matter in industrial markets?

Non-members of the Academy of Management can purchase access to individual publication articles.Perceptual customer constructs can be central to leverage market intelligence for optimizing customer relationships. The purpose of this paper is to contribute to our understanding of the relationship between perceptual customer metrics that relate to relationship quality (i.e., customer orientation, customer satisfaction, attitudinal loyalty, customer influence on supplier innovation) and behavioral outcomes (i.e., customer account profitability, share of wallet). The paper integrates stated and revealed preference data from a multinational mechanical engineering firm and its global customer base. Results from latent class analysis and fractional logistic regressions highlight both the role of customer perception heterogeneity, and that of nonlinearities between perceptual constructs and behavioral metrics, for targeting behavioural outcomes. They also suggest that attitudinal loyalty and customer satisfaction are highly relevant aspects of relationship quality with respect to share of wallet. However, fractional logistic regression results also indicate that customer perceptions of the supplier’s product innovativeness, and perceptions of customer influence on supplier innovation, are likely not relevant aspects of relationship quality.Peer reviewe

Kartierung und Regionalisierung von Permafrostindikatoren im Rieserfernergebiet (Südtirol/Osttirol)

In the Rieserferner-Ahrn Nature Park (South Tyrolean Alps, Italy) a detailed mapping of the spatial distribution of permafrost phenomena is carried out in order to provide the basis for natural hazards analyses. The study is based on the surveying of the characteristics of geomorphological, hydrological and physical permafrost indicators, such as rock glaciers, ice-cored debris and moraine deposits, perennial snow patches, temperatures at the base of the winter snow cover (BTS) as well as temperatures and electrical conductivity of melt water. By means of a statistical model an analysis is made as to what extent the spatial density of perennial snow patches is appropriate to forecast the spatial distribution of permafrost. First results show that this approach - that was not considered useful so far - provides a significant approximation for determining the lower limit of discontinuous permafrost areas

Systemic therapy of Cushing’s syndrome

Cushing’s disease (CD) in a stricter sense derives from pathologic adrenocorticotropic hormone (ACTH) secretion usually triggered by micro- or macroadenoma of the pituitary gland. It is, thus, a form of secondary hypercortisolism. In contrast, Cushing’s syndrome (CS) describes the complexity of clinical consequences triggered by excessive cortisol blood levels over extended periods of time irrespective of their origin. CS is a rare disease according to the European orphan regulation affecting not more than 5/10,000 persons in Europe. CD most commonly affects adults aged 20–50 years with a marked female preponderance (1:5 ratio of male vs. female). Patient presentation and clinical symptoms substantially vary depending on duration and plasma levels of cortisol. In 80% of cases CS is ACTH-dependent and in 20% of cases it is ACTH-independent, respectively. Endogenous CS usually is a result of a pituitary tumor. Clinical manifestation of CS, apart from corticotropin-releasing hormone (CRH-), ACTH-, and cortisol-producing (malign and benign) tumors may also be by exogenous glucocorticoid intake. Diagnosis of hypercortisolism (irrespective of its origin) comprises the following: Complete blood count including serum electrolytes, blood sugar etc., urinary free cortisol (UFC) from 24 h-urine sampling and circadian profile of plasma cortisol, plasma ACTH, dehydroepiandrosterone, testosterone itself, and urine steroid profile, Low-Dose-Dexamethasone-Test, High-Dose-Dexamethasone-Test, after endocrine diagnostic tests: magnetic resonance imaging (MRI), ultra-sound, computer tomography (CT) and other localization diagnostics. First-line therapy is trans-sphenoidal surgery (TSS) of the pituitary adenoma (in case of ACTH-producing tumors). In patients not amenable for surgery radiotherapy remains an option. Pharmacological therapy applies when these two options are not amenable or refused. In cases when pharmacological therapy becomes necessary, Pasireotide should be used in first-line in CD. CS patients are at an overall 4-fold higher mortality rate than age- and gender-matched subjects in the general population. The following article describes the most prominent substances used for clinical management of CS and gives a systematic overview of safety profiles, pharmacokinetic (PK)-parameters, and regulatory framework